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Abstract—We previously described a ﬁlament-based anti-
body recognition assay (FARA) that generates ELISA-like
sandwich structures immobilized on a ﬁlament. FARA
allows the coupling of antibodies to precise locations along
a ﬁlament, on-line ﬂuorescence detection of captured path-
ogen, and feedback-directed ﬁlament motion. These proper-
ties suggest that this approach might be useful as an
automated means to rapidly classify unknown pathogens.
In this report, we describe validation of the novel decision
tree aspect of this technology using mammalian reovirus.
Based on available antibodies, we developed a decision tree
algorithm to detect virus with increasing speciﬁcity at each
level of the tree. Using three strains of reovirus and a
bacteriophage control, our system correctly classiﬁed the
reovirus strains at a concentration of 210
12 virions ml
)1
and M13K07 phage at 310
11 virions ml
)1. Classiﬁcation of
reovirus strain type 3 Dearing (T3D) required three levels of
testing: general reovirus classiﬁcation in level 1, serotype 3
classiﬁcation in level 2, and ﬁnal T3D strain classiﬁcation in
level 3. Strain T3SA + also required three levels of testing
before a ﬁnal classiﬁcation was returned in level 3. Classi-
ﬁcation of strain type 1 Lang (T1L) required two levels of
testing. M13K07 phage detection required only one level of
testing for classiﬁcation. These results indicate that auto-
mated pathogen classiﬁcation using FARA is feasible.
Furthermore, the simplicity of the design could be exploited
for development of more complex sub-classiﬁcation networks
with additional levels and branches.
Keywords—Virus detection, Virus classiﬁcation, Fluores-
cence detection, Pathogen detection.
INTRODUCTION
Identiﬁcation of speciﬁc pathogens is essential for
the selection of pathogen-speciﬁc treatments, mini-
mizing the spread of infection, and monitoring for
long-term complications. Currently, speciﬁc pathogen
identiﬁcation is achieved through available RT-PCR
and antibody-based strategies. In the clinic, these tests
are usually applied consecutively to evaluate for the
presence of the most likely to least likely pathogen
based on patient ﬁndings. An automated classiﬁcation
strategy that is less dependent on clinical knowledge
but achieves rapid accurate identiﬁcation of a single
pathogen from among a group of possible pathogens is
currently unavailable.
Our previously described ﬁlament-based antibody
recognition assay (FARA) employs antibodies immo-
bilized at known locations along a ﬁlament to detect
speciﬁc pathogens.
9,10 The ﬁlament is pulled through a
series of small reaction chambers, and pathogens, if
present, are captured by ﬁlament-bound antibodies.
Detection of pathogen binding is achieved by using a
ﬂuorescently labeled second antibody speciﬁc for the
pathogen.
FARA was ﬁrst reported using immobilized anti-
M13K07 antibody to detect M13K07 phage.
10 This
virus and antibody pair provided a well-characterized
test system to demonstrate the feasibility of a ﬁlament-
based, pathogen-detection platform. However, in this
ﬁrst generation approach, the ﬁlaments were removed
from the system for ﬂuorescence scanning. Subsequent
improvements to FARA include an integrated ﬂuo-
rescence detector and a feedback algorithm to control
ﬁlament position.
9 The integrated detector enables
adaptive pathogen detection in which regions of
interest along the ﬁlament can be reincubated in the
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1778appropriate reaction chambers to increase ﬁlament
ﬂuorescence when the initial signal is low.
In this report, we describe a small-scale test of the
use of a simple classiﬁcation tree together with feed-
back-controlled FARA to identify four viruses. The
feedback feature of online FARA is used to guide the
selection of subsequent tests within the classiﬁcation
tree. Unnecessary tests are not performed, and each
subsequent test becomes more speciﬁc for a single
pathogen. These results establish FARA as a robust
platform for classiﬁcation of diverse pathogens.
MATERIALS AND METHODS
Cells and Viruses
Murine L929 (L) cells were cultured in suspension in
Joklik’s modiﬁed Eagle’s medium supplemented to
contain 5% fetal bovine serum, 2 mM L-glutamine,
100 U mL
)1 penicillin, 100 lgm L
)1 streptomycin,
and 0.25 g mL
)1 amphotericin-B. Reovirus strains
T1L and T3D are laboratory stocks. T3SA + is a
monoreassortant virus isolated from L cells co-infected
with T1L and T3C44MA.
1 T3SA + contains the S1
gene segment from the type 3 parental strain and all
other gene segments from T1L.
1 Reovirus particles
were puriﬁed as previously described.
1, 3, 6 L cells were
inoculated with second-passage L-cell lysate stocks of
twice plaque-puriﬁed reovirus at a multiplicity of
infection of 10 plaque-forming units per cell. Virus was
puriﬁed from infected cells by freon extraction and
CsCl-gradient centrifugation. Puriﬁed M13K07 virus
was obtained from the Vanderbilt Molecular Recog-
nition Core.
Antibodies
Mouse monoclonal antibodies 4F2, 5C6, 8H6, and
9BG5 speciﬁc for reovirus proteins
2,12,13 (Table 1) were
puriﬁed from mouse hybridoma supernatants using
Protein A column chromatography. Anti-M13K07
monoclonal antibody was purchased from Amersham
Biosciences (Piscataway, NJ).
Antibodies 4F2 and 8H6 were used for ﬂuorescence
detection of virus (step 4, Table 2) and were labeled
with Alexa Fluor 555 or Alexa Fluor 647 (AF555 or
AF647, Molecular Probes, Eugene, OR), respectively,
according to the manufacturer’s instructions (Molec-
ular Probes). Labeled antibodies were puriﬁed using
PD-10 size-exclusion chromatography (Amersham
Biosciences). Antibody concentration and number of
ﬂuores per labeled antibody were determined by using
absorbance measurements at 280 nm and the peak
absorbance wavelength of each label. Aliquots of both
labeled and unlabeled antibodies were stored at )20C,
and working solutions were kept at 4C. Final anti-
body concentration was adjusted immediately prior to
experiments.
Filament Preparation
Capture antibodies were passively adsorbed to the
ﬁlament surface in groups of three by placing the ﬁl-
ament across the concave teeth of a PhastGel sample
applicator (Amersham Biosciences) (Fig. 1). Three
capture-antibody regions, corresponding to the three
levels of testing, were prepared along each ﬁlament
using three applicator combs glued end to end. Anti-
body solution pipetted onto the ﬁlament without the
comb spread unimpeded along the ﬁlament. Surface
tension within the teeth of the comb overcame this
tendency and produced a small, distinct circumferen-
tial band of immobilized antibody. Antibody was
spotted in a volume of 0.75 lL and allowed to pas-
sively adsorb to the ﬁlament for 45 min in a humidiﬁed
box. Following incubation at 25C, ﬁlaments were
rinsed in phosphate buffered saline with 0.1% Tween
20 (PBS-T) and threaded through the reaction cham-
bers for virus detection experiments. Preliminary
experiments were performed to determine the optimal
concentration of each capture antibody.
Red ﬁngernail polish (Poisonberry, Noxel Cor-
porartion, Hunt Valley, MO) was used as a visible and
ﬂuorescent ﬁducial marker to identify the leading and
trailing edges of capture-antibody regions during
experiments and during laser scanning. The polish was
applied by pipette between the teeth of the comb
ﬂanking the antibody region. A simple bar code system
was used to identify each of the three capture-antibody
regions. The ﬁrst and second regions were preceded by
a single ﬁducial marker, and the third region was
preceded by two ﬁducial markers.
Micro-reaction Chambers
Glass microreaction chambers were fashioned from
0.25 inch stock tubing into 75 mm lengths. The ends
were ﬂared outward to facilitate movement of the ﬁl-
ament through the chambers. Interior diameters of the
chambers were 1 or 2 mm depending on the required
Table 1. Antibody speciﬁcity.
Antibody Protein speciﬁcity
Reovirus strain
T1L T3D T3SA+
5C6 T1 r1 + ))
9BG5 T3 r1 ) ++
8H6 T1 and T3 l1 ++ +
4F2 T3D r3 ) + )
Autonomous Reovirus Strain Classiﬁcation 1779reaction volume (Table 2). Chambers were carefully
positioned in a straight line on the top of a horizontal
aluminum stage using machined aluminum mounts.
9
Fine adjustment of chamber position was achieved by
using oblong mounting holes on each mount. PBS-T
was used in all wash chambers and for virus and
labeled antibody solutions. Reovirus was used at a
concentration of 210
12 virions mL
)1, and phage
M13K07 was used at a concentration of 310
11 viri-
ons mL
)1. Detecting antibodies were present in the
detecting-antibody chamber at a concentration of
approximately 40 lgm L
)1 for each antibody in the
three antibody mixture. Solutions were added to
appropriate chambers at the initiation of experiments
and used for all three levels of testing (Table 2). If
testing proceeded to level three, ﬂuid loss from the
chambers was monitored and replenished if necessary.
Filament Control
Movement of the ﬁlament and, therefore, the anti-
body bands through the chambers, was achieved by
using a rotary stage to wind or unwind the ﬁlament
around a spindle. A small weight was attached to the
opposite end of the ﬁlament to maintain a constant
tension. Filament positioning to within several microns
was achieved by using a rotary stage encoder from
Yaskawa Instruments (Waukegan, IL) and a custom
control algorithm written as a LabView Virtual
Instrument (VI) (National Instruments, Austin, TX).
Parameters including ﬁlament speed and residence
times within chambers were controlled by using the
LabView software interface.
Between chambers, the speed of the ﬁlament was
1 cm sec
)1. Within each chamber, the capture-anti-
body region undergoing processing was oscillated
2.5 cm back and forth at a speed of 1 cm sec
)1 to
increase interactions between immobilized molecular
structures attached to the ﬁlament and the molecular
species in solution. Within the detector, ﬁlament speed
was 4 cm sec
)1.
Lasers and PMTs
Filament ﬂuorescence was measured by passing the
ﬁlament between two diode lasers. The two laser
excitation sources were attached to either side of a
detection chamber (Fig. 2). Laser 1 (638 nm, 25 mW
diode laser; Coherent, Santa Clara, CA) was used to
excite the antibody tag AF647. Laser 2 (532 nm,
20 mW diode-pumped, solid state laser; B&W Tek,
Inc., Newark, DE) was used to excite the antibody tag
AF555. The effective power of laser 1 was reduced to
approximately 5 mW by using a polarizer and an
excitation slit. Laser 2 was not attenuated. Two
Hamamatsu R928 photomultiplier tubes (PMT) were
attached to the top and bottom of the sample chamber
and powered by 850 and 800 V signals for the AF647
and AF555 channels, respectively. Current from the
PMT was converted to voltage by using transimped-
ance ampliﬁers that ampliﬁed the signal by a factor of
10
6 for AF647 and 10
5 for AF555. Voltage was sam-
pled at a rate of 800 samples sec
)1 by using a digital
acquisition board from National Instruments (Daq-
PAD 6020E). Fluorescence signal was acquired as a
function of ﬁlament position by using LabView.
Table 2. The ﬁve reaction chambers in FARA processing
Chamber Description Solution Incubation time
Chamber ID /
Volume (mm / ll)
1 Block/Wash Filament PBS-T
a 15 min 2/235
2 Virus Incubation Unknown Virus 40 min 1/60
3 Wash PBS-T 1 min 2/235
4 Detecting Antibody Incubation Fluorescently Labeled Detecting Antibody 5 min 1/60
5 Wash PBS-T 1 min 2/235
aTween-20 (0.1%) was added to PBS as a blocking agent.
FIGURE 1. Schematic of a device for adsorption of capture antibodies to the ﬁlament. The ﬁlament is placed within the concave
teeth of a PhastGel applicator to localize the spotted antibody to a small circumferential band around the ﬁlament.
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ﬁlament regions were cut and scanned again in a
microarray ﬂatbed scanner (GenePix 4000B, Axon
Instruments, Union City, CA).
Filters
Filter sets were placed in the light path between the
sample chamber and the photomultipliers (Fig. 2).
Long-pass ﬁlters with cutoffs at 685 nm (Chroma,
Rockingham, VT) and 665 nm (Melles Griot,
Rochester, NY) were combined to reduce reﬂected
laser light from the AF647 laser. For the AF555
channel, two long-pass ﬁlters (570 nm cutoff, Melles
Griot) were combined with a bandpass ﬁlter centered
at 565 nm (30 nm bandwidth, Chroma) to reduce
reﬂected light.
Classiﬁcation Algorithm
The LabView program coordinated all ﬁlament
movement, ﬁlament scanning, and feedback control.
Elements of the feedback control are described by the
nodes of the decision tree used to classify the viruses
shown in Fig. 3. The ﬂuorescent ﬁducial markers on
either side of the capture-antibody region produced
characteristically sharp emission peaks. Since the
physical location of the immobilized antibody posi-
tions between the markers was known, experimental
conclusions were based on the distance of the ﬁrst
detected peak from the initial ﬂuorescent marker.
The ﬁlament-control program was designed to ﬁnd
each peak, calculate its location along the ﬁlament, and
make a decision about additional tests. Spatially
localized ﬂuorescence from the ﬁlament was measured
as a 0–14 V signal from the transimpedance ampliﬁer.
Voltage data from the scan were used as input data by
a peak-detection function in LabView. The LabView
peak detector ﬁt a quadratic polynomial to sequential
sets of points depending on a width parameter entered
by the user. Data were then compared to a threshold
parameter, also entered by the user, to identify peaks.
A binary decision to stop or continue testing was based
on the location and number of peaks found. Peak-
detection threshold parameters were deﬁned as 0.3 V
(approximately three times background) with a width
of 30 data points, which corresponded to a width
slightly larger than the physical width of the comb
tooth.
A common set of parameters was used in all experi-
ments based on previous work with M13K07.
10 A
ﬁlament region containing three capture antibodies and
two ﬁducial markers was incubated within each cham-
ber for the times shown in Table 2. Each of the capture-
antibody regions contained a PBS negative control in
the ﬁrst position. In level one the second position
was a mixture of 9BG5 and 5C6 (0.25 mg mL
)1,
0.2 mg mL
)1). The third position was anti-M13K07
(0.5 mg mL
)1). In levels two and three, the negative
control position was followed by 9BG5 (mg mL
)1)i n
the second position and 5C6 (0.2 mg mL
)1) in the third
position.
The logic encoded in the decision tree shown in
Fig. 3 was followed. In level 1, if ﬂuorescence was
detected from the anti-M13K07 position of the ﬁrst
region of the ﬁlament, a classiﬁcation of M13K07 virus
was made, and no further testing was conducted. If
ﬂuorescence was detected in the 9BG5/5C6 region, a
classiﬁcation of reovirus was made and the ﬁlament
was advanced to the appropriate region for level 2
testing, where a more speciﬁc test for reovirus was
performed. In level 2 testing, ﬂuorescence from the 5C6
region indicated a serotype 1 reovirus, which in this
scheme corresponded to reovirus T1L. A classiﬁcation
of T1L represented an endpoint in the decision tree,
and testing was discontinued. Fluorescence from the
9BG5 region indicated the presence of a serotype 3
reovirus, and the program advanced the ﬁlament for
further subtyping in level 3. Level 3 testing used AF555
conjugated 4F2 antibody as the detecting antibody and
a second detection channel with a green excitation
laser. If ﬂuorescence was found in the 9BG5 region
using this channel, a classiﬁcation of reovirus T3D was
made and testing along that branch ended. If no ﬂu-
orescence was detected from the second channel for
that region, the program ended with a classiﬁcation of
reovirus T3SA+ .
If no peaks were found between the ﬁducial mark-
ers, a message was generated indicating that no virus
was found. Similarly, if a peak was detected in the
negative control region of the ﬁlament, a warning
FIGURE 2. Schematic of lasers and photomultipliers (PMT)
to detect online ﬂuorescence of the ﬁlament. The ﬁlament is
moved (arrow) through a rectangular sample chamber with a
laser excitation source attached to either side. Photomultiplier
tubes are attached to the top and bottom of the chamber.
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ble, this situation did not arise during testing.
RESULTS
FARA utilizes a polyester ﬁlament with circumfer-
ential bands of immobilized antibody that is passed
through a series of ﬁve glass micro-reaction chambers
that are similar to the ﬁve major steps of an ELISA
(Table 2). In the ﬁrst reaction chamber of the FARA
approach employed in this study, capture antibody
coupled to the ﬁlament was rehydrated. In this chamber
the ﬁlament also was blocked to prevent non-speciﬁc
bindingofvirus.Inthesecondchamber,theimmobilized
capture antibody was incubated with virus solution. In
this chamber, if virus in solution bound to antibody
coupled to the ﬁlament, then the virus became coupled
to the ﬁlament via this interaction. In the third chamber,
non-speciﬁcally bound virus was removed by washing
before incubation with a ﬂuorescently labeled detecting
antibody in the fourth chamber. A ﬁnal wash in the ﬁfth
chamber removed non-speciﬁcally bound detecting
antibody. The capture antibody region was then passed
through an integrated ﬂuorescence detector.
In these experiments, the test virus was classiﬁed
with greater speciﬁcity at each level of a decision tree
(Fig. 3). Representative ﬂuorescence signals in volts
obtained during testing for phage M13K07 and
reoviruses T1L, T3D, and T3SA+ are shown in Fig. 4.
Labels for the PBS control position and the antibodies
in each capture antibody position are shown adjacent
to the ﬁlament. The speciﬁcity of each test antibody for
its corresponding virus was high, with little or no
cross-reactivity. No signal was detected in the PBS
negative-control position.
Detection of M13K07 was achieved by level 1 test-
ing. Strong ﬂuorescence was observed in the anti-
M13K07 position but not in the 9BG5/5C6 or PBS
positions (Fig. 4a). This ﬁnding indicated capture of
the phage M13K07 by the anti-M13K07 capture
antibody. For detection of M13K07, AF647 conju-
gated anti-M13K07 was used. Because a classiﬁcation
of M13K07 was made, the other two capture regions of
the ﬁlament were not evaluated.
Detection of the reovirus strains employed in this
study required analysis beyond level 1. Level 1 testing
indicated the presence of a reovirus for all three strains
with a peak in the second position corresponding to
virus capture by the 9BG5/5C6 antibody mixture. In
level 2 testing, strain T1L was detected in the 5C6
antibody position but not in the 9BG5 or PBS posi-
tions (Fig. 4b). In this case, the capture and detecting
antibodies differed. Because a reovirus T1L classiﬁca-
tion was made, the third capture region of the ﬁlament
was not evaluated.
For reovirus T3D, level 1 testing indicated the
presence of a reovirus with a peak in the second po-
sition corresponding to virus capture by 9BG5/5C6
(data not shown). Level 2 testing showed a distinct
FIGURE 3. Decision-tree algorithm to classify virus strains. The ﬁlament control program enters the decision tree from the top at
level 1 and, based on the type of virus found at each level, follows different branches of the decision tree. When reovirus is
detected at level one, the ﬁlament is moved forward to the next antibody region for level 2 testing. If a serotype 3 reovirus strain is
detected (T3D or T3SA+ ) at level 2, testing continues to level 3 to distinguish between these strains.
STONE et al. 1782peak in the 9BG5 antibody position (Fig. 4c, red
curve). In this case, 8H6 antibody labeled with AF647
was the detecting antibody indicating a type 3 reovirus.
Level 3 testing showed a distinct peak in the 9BG5
antibody position (Fig. 4c, green curve). In this case,
4F2 antibody labeled with AF555 was the detecting
antibody. Neither curve showed cross reactivity of
reovirus T3D with the immobilized 5C6 region or the
negative-control PBS region.
For reovirus T3SA+ , level 1 testing indicated the
presence of a reovirus with a peak in the second po-
sition corresponding to virus capture by 9BG5/5C6
(data not shown). Level 2 testing yielded a distinct
peak in the 9BG5 antibody position (Fig. 4d, red
curve), like the result obtained with T3D. However,
level 3 testing with 4F2 did not yield a positive signal in
the 9BG5 antibody position, indicating that the cap-
tured virus was not T3D. No detectable cross reactivity
was found in the 5C6 antibody region or the negative-
control PBS region. Thus, the virus was classiﬁed as
T3SA+.
DISCUSSION
In this study, we demonstrated the feasibility of a
FARA pathogen-classiﬁcation approach using a well-
characterized virus system. Three reovirus strains and
one phage were successfully classiﬁed by performing
sequential antibody-binding assays directed by the
decision tree. The structure of the decision tree was
based on published characteristics of each virus strain
and the known speciﬁcity of each antibody. Because
the capture antibodies were arrayed at known loca-
tions along the ﬁlament, and the ﬂuorescence of the
detection antibodies was measured as a function of
ﬁlament location, an increase in ﬁlament ﬂuorescence
at a particular location indicated antibody interaction
with the virus. For each virus strain tested, the
expected ﬂuorescence peaks were observed, and the
correct classiﬁcation was made. Moreover, successful
transit of all decision tree branches was demonstrated.
The biochemical components of FARA are similar
to those used in standard ELISAs. Both assays create a
dual-antibody sandwich that results in similar detec-
tion limits for M13K07 for FARA and ELISA.
10 One
of the virus-speciﬁc antibodies acts as the capture
antibody, and the second acts as the detecting anti-
body. The main difference in the biochemistry of the
two assays is that, in the current implementation of
FARA, enzyme ampliﬁcation is not utilized. Like
ELISA, FARA utilizes antibodies adsorbed to the
surface of a substrate to capture virus from solution.
The capacity of bound antibody to retain its antigen-
binding activity is essential to the success of both
assays. Each of the immobilized test antibodies in our
system retained functionality and bound its corre-
sponding virus (Fig. 4). The absence of peaks in the
negative-control positions and in positions occupied by
antibodies not speciﬁc to the test virus demonstrates
minimal cross reactivity in the FARA platform
employed in this study.
We chose reovirus as a test system to show clinical
relevance and to avoid potential safety concerns in the
laboratory. Reovirus has been used as a model to study
mechanisms of viral pathogenesis in mice.
14 Although
it is a human pathogen, it is rarely associated with
human disease.
11 Many reovirus ﬁeld-isolate strains
have been characterized,
4,7,8 and a broad array of
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FIGURE 4. Fluorescence intensity in volts as a function of
ﬁlament position for M13K07 phage (A) and reoviruses T1L
(B), T3D (C), and T3SA+ (D). The immobilized capture anti-
body positions on the ﬁlament are labeled within each panel.
Captured virus was detected by a ﬂuorescently labeled sec-
ond antibody (anti-M13K07 [red], 8H6 [red], or 4F2 [green]).
Corresponding images of the scanned ﬁlaments are shown at
the top of each graph. Each panel shows a representative
experiment of three performed.
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varying speciﬁcity.
12
We found that not every antibody tested was suit-
able for use as an immobilized capture antibody.
Neither antibody 8H6 nor 4F2 bound virus when
immobilized on the ﬁlament, even after virus incuba-
tion time was increased to greater than 100 min (data
not shown). It is possible that these antibodies undergo
conformational changes when passively adsorbed to a
solid substrate, rendering them inactive. Alternatively,
these antibodies may be incapable of antigen binding
when immobilized as a consequence of steric hin-
drance. Antibodies 8H6 and 4F2 recognize the l1a n d
r3 proteins, respectively,
12 which form the bulk of the
viral outer capsid.
5 It is possible that extension of the
viral attachment protein r1 may shield the l1 and r3
proteins from binding to the 8H6 and 4F2 antibodies
on the ﬁlament surface. This conclusion also is con-
sistent with our observation that 9BG5 and 5C6 were
both excellent capture antibodies, since they recognize
the r1 protein, which extends farthest from the viral
capsid. The failure of the 8H6 and 4F2 antibodies to
function as effective capture antibodies complicated
our virus detection scheme. Although 8H6 is not
serotype-speciﬁc and should bind all reovirus strains,
we could not use this antibody as the immobilized
capture antibody for level 1 testing. Antibodies 5C6
and 9BG5 are speciﬁc for serotype 1 and serotype 3
reovirus strains, respectively;
12 therefore, we immobi-
lized a mixture of these antibodies for detection of all
reovirus isolates in level 1. Although 4F2 recognizes
most type 3 strains, T3SA+ is a reassortant virus that
contains a r3-encoding gene segment from T1L.
1 As a
result, 4F2 does not recognize T3SA+ and is speciﬁc
only for T3D in our scheme. Since 4F2 could not be
used as a capture antibody in level 3, we incorporated a
ﬂuorescently labeled 4F2 antibody as a detecting
antibody in solution.
Although the nature of the biochemical interactions
is similar in FARA and ELISA, the capture antibody
employed in a standard ELISA is static, and solutions
are changed in the well-plate in a ﬁxed sequence. In
FARA, the capture antibody is attached to a mobile
substrate, and solutions are changed by positioning the
ﬁlament in diﬀerent solution chambers. As we have
shown previously, this gives FARA a sensitivity limit
similar to ELISA on the order of 10
7 virus particles.
10
A major advantage of FARA is that it is dynamic and
allows modiﬁcation of processing in response to
results.
9 Virus incubation time with the capture anti-
body can be reduced to as low as one minute
depending on the virus concentration and antibody
afﬁnity, reducing the overall assay duration. On the
other hand, the incubation time can be increased in
order to increase sensitivity.
9 Moreover, because the
ﬁlament is mobile, the capture antibody is brought to
the virus solution, thus enabling use of capture anti-
bodies with different speciﬁcities to interrogate a single
aliquot of virus solution.
Attachment of the capture antibody to a mobile
ﬁlament in FARA makes accurate positioning of the
ﬁlament and correct identiﬁcation of the capture
antibody regions essential for virus strain classiﬁca-
tion. These parameters are particularly important in
multilevel testing of the type used in our study. A
simple bar code system based on ﬂuorescent ﬁducial
markers was used to identify the leading edge of each
of the capture antibody regions and position the ﬁla-
ment in the reaction chambers. The pattern of the
ﬂuorescent marks also was used to identify the level of
testing. Since our simple test system involved three
levels, and testing always began in level 1, only sear-
ches for patterns containing one or two ﬂuorescent
marks corresponding to levels two and three were
required. However, this simple approach allows for the
incorporation of more complex bar codes using addi-
tional spots or patterns of spots.
This study demonstrates the feasibility of an auto-
mated system for diagnosing speciﬁc virus strains.
Although the scheme we report is a relatively simple
implementationofthissystem,morecomplexdesignsare
possible. For example, each antibody capture region
could contain additional antibodies. In addition, there is
essentially no limit to the overall length of the ﬁlament,
whichwould allow the incorporation ofmany additional
testing regions. The sensitivity of FARA could also be
increased by the use of quantum-dot labeled detection
antibodies as well as a more sensitive ﬂuorescence
detection system. The most important requirement is the
availability of a wide range of antibodies to the speciﬁc
pathogens of interest. Such a strategy may have appli-
cations for detecting speciﬁc pathogens from complex
mixtures. This approach would have both clinical and
environmental applications.
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